This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Women with mutations in specific cancer predisposition genes have an increased risk for developing ovarian cancer. This risk may be as high as 60% in some families. Ovarian cancer is difficult to detect early, and most women present at an advanced stage at which time cure is unlikely. CA125 is a protein that is often elevated in women with ovarian cancer and is being evaluated as a means of early detection of ovarian cancer. Since ovarian cancer may go from undetectable to incurable relatively rapidly, annual measurements of CA125 may miss many cases of curable ovarian cancer. This study is a multi-institutional pilot trial sponsored by the Cancer Genetics Network. Utah is one of six sites in the network. We will screen high-risk women for ovarian cancer with CA125 at three-month intervals. Baseline CA125 values, a priori risk of ovarian cancer based on age and family history, and change in CA125 values with time are used to calculate the risk of ovarian cancer. If the study design and preliminary outcomes appear feasible and promising, the study will be expanded to allow for definitive assessment of efficacy of screening.
Showing the most recent 10 out of 535 publications
